Preliminary Communication

Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer

Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention & Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, PR China

^‡These authors contributed equally to this work

Search for more papers by this author

Xingping Ge^‡

The Second Department of Radiotherapy, Yantai Shan Hospital of Yantai City, Yantai 264001, PR China

^‡These authors contributed equally to this work

Search for more papers by this author

Jia Tian

Search for more papers by this author

Jia Wei

Search for more papers by this author

Lujun Zhao

*Author for correspondence:

E-mail Address: zhaolujun@tjmuch.com

https://orcid.org/0000-0001-5960-0201

Search for more papers by this author

Published Online:20 Jul 2020https://doi.org/10.2217/fon-2020-0289

View article

Abstract

Aim: To evaluate the prognostic role of EGFR mutations in patients with multi-site metastases from non-small-cell lung cancer (NSCLC). Patients & methods: A total of 215 advanced NSCLC patients with multi-site metastases were included. The overall survival (OS) was the primary end point. Results: EGFR tyrosine kinase inhibitors (TKIs) significantly improved the OS in patients with brain metastases (p = 0.031) and bone metastases (p = 0.048). Meanwhile, it prolonged the OS in patients with lung or adrenal metastases, but not in patients with liver metastases. However, in patients without liver metastases, EGFR TKIs significantly improved the OS (p < 0.001). Conclusion: EGFR TKIs improved the prognosis in NSCLC patients with brain, bone, lung and adrenal metastases, but not in patients with liver metastases.

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374–1403 (2013).
Medline CASGoogle Scholar
3. Riihimäki M, Hemminki A, Fallah M et al. Metastatic sites and survival in lung cancer. Lung Cancer 86(1), 78–84 (2014).
Medline CASGoogle Scholar
4. Dogan S, Shen R, Ang DC et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res. 18(22), 6169–6177 (2012).
Medline CASGoogle Scholar
5. Mok TS, Wu YSJTJOE-BM. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947 (2009). •• Compared with chemotherapy, targeted therapy improved the prognosis in pulmonary adenocarcinoma.
Medline CASGoogle Scholar
6. Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735–742 (2011). •• Demonstrated that tyrosine kinase inhibitors (TKIs) as first-line treatment improved the prognosis in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Medline CASGoogle Scholar
7. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014).
Medline CASGoogle Scholar
8. Shi YK, Wang L, Han BH et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a Phase 3, open-label, randomized study. Ann. Oncol. 28(10), 2443–2450 (2017).
Medline CASGoogle Scholar
9. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239–246 (2012).
Medline CASGoogle Scholar
10. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
Medline CASGoogle Scholar
11. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010).
Medline CASGoogle Scholar
12. Fukuoka M, Wu YL, Thongprasert S et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29(21), 2866–2874 (2011).
Medline CASGoogle Scholar
13. Wu Y-L, Zhou C, Hu C-P et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol. 15(2), 213–222 (2014).
Medline CASGoogle Scholar
14. Yang JC-H, Wu Y-L, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, Phase 3 trials. Lancet Oncol. 16(2), 141–151 (2015).
Medline CASGoogle Scholar
15. Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018).
Medline CASGoogle Scholar
16. Ramalingam SS, Vansteenkiste J, Planchard D et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382(1), 41–50 (2020).
Medline CASGoogle Scholar
17. Wu KL, Tsai MJ, Yang CJ et al. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer 88(2), 187–194 (2015). •• Retrospective study that found liver metastasis was an independent prognostic factor for poor progression-free survival and overall survival in lung adenocarcinoma patients with EGFR-sensitive mutations who accepted the first-line target therapy for the first time.
MedlineGoogle Scholar
18. Castanon E, Rolfo C, Vinal D et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. J. Transl. Med. 13, 257 (2015). •• Found that liver metastases did not have any significant effect on the prognosis of NSCLC patients with EGFR mutations who received the first-line targeted therapy.
MedlineGoogle Scholar
19. Reck M, Mok TSK, Nishio M et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label Phase 3 trial. Lancet Respir. Med. 7(5), 387–401 (2019). •• Prospective study that demonstrated bevacizumab prolonged the overall survival in NSCLC patients with liver metastases.
Medline CASGoogle Scholar
20. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa KJMO. Liver metastasis at the time of initial diagnosis of lung cancer. Med. Oncol. 20(1), 25–28 (2003).
MedlineGoogle Scholar
21. Nakazawa K, Kurishima K, Tamura T et al. Specific organ metastases and survival in small cell lung cancer. Oncol. Lett. 4(4), 617–620 (2012).
MedlineGoogle Scholar
22. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5(3), 203–220 (2007). •• Elaborated the complementary roles of VEGF and EGFR signaling pathways in tumorigenesis.
Medline CASGoogle Scholar
23. Langer C, Soria JC. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 11(2), 82–90 (2010). •• Detailed the role of anti-EGFR and anti-VEGF therapies in NSCLC.
Medline CASGoogle Scholar
24. Tumeh PC, Hellmann MD, Hamid O et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol. Res. 5(5), 417–424 (2017).
Medline CASGoogle Scholar
25. Pao W, Ooi CH, Birzele F et al. Tissue-specific immunoregulation: a call for better understanding of the “immunostat” in the context of cancer. Cancer Discov. 8(4), 395–402 (2018).
Medline CASGoogle Scholar
26. Facciabene A, Peng X, Hagemann IS et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475(7355), 226–230 (2011).
Medline CASGoogle Scholar
27. Chiu DK, Xu IM, Lai RK et al. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology (Baltimore, MD.) 64(3), 797–813 (2016).
Medline CASGoogle Scholar
28. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(11), 2544–2555 (2005).
Medline CASGoogle Scholar
29. Saito H, Fukuhara T, Furuya N et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, Phase 3 trial. Lancet Oncol. 20(5), 625–635 (2019).
Medline CASGoogle Scholar
30. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378(24), 2288–2301 (2018).
Medline CASGoogle Scholar

Vol. 16, No. 26

Metrics

Downloaded 140 times

History

Received 3 April 2020

Accepted 16 June 2020

Published online 20 July 2020

Published in print September 2020

Information

Keywords

Author contributions

All authors contributed to the study conception and design. Conceptualization, methodology and formal analysis were performed by C Meng and X Ge. Investigation was performed by C Meng, X Ge, J Tian and J Wei. The first draft of the manuscript was written by C Meng. The manuscript review and editing were performed by L Zhao and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical Conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download